Login / Signup

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.

Vignesh NarasimhanJosephine A WrightMichael ChurchillTongtong WangRachele RosatiTamsin R M LannaganLaura VrbanacAnne B RichardsonHiroki KobayashiTimothy PriceGayle X Y TyeJulie MarkerPeter J HewettMichael P FloodShalini PereiraG Adam WhitneyMichael MichaelJeanne TieSiddhartha MukherjeeCarla GrandoriAlexander G HeriotDaniel L WorthleyRobert George RamsaySusan L Woods
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our approach is feasible, reproducible, and can guide novel therapeutic choices in this poor prognosis cohort, where new treatment options are urgently needed. This platform is relevant to many solid organ malignancies.
Keyphrases
  • poor prognosis
  • long non coding rna
  • high throughput
  • emergency department
  • stem cells
  • drug induced
  • adverse drug
  • bone marrow
  • mesenchymal stem cells
  • induced pluripotent stem cells
  • single cell
  • electronic health record